Michael Huang

Frequency Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the business of developing therapeutics to activate a person's innate regenerative potential to restore function. The firm is also involved in creating and commercializing therapeutics to potentially transform the lives of individuals by repairing or reversing damage done to cells, tissue, and organs. The company was founded by Robert S. Langer, David L. Lucchino, Christopher R. Loosey, and Will J. McLean on November 13, 2014 and is headquartered in Lexington, MA.

Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA.

Regenacy Pharmaceuticals LLC operates as a clinical-stage biopharmaceutical company. It develops treatments for diabetic and peripheral neuropathies. The firm provides treatments through regeneration of normal protein function using oral, isoform selective histone deacetylase enzyme inhibitors. It provides treatment for diseases such as sickle cell disease, ß-thalassemia, leukemia, and cognitive dysfunction in neurological disorders. The company was founded by Marc A. Cohen in December 2016 and is headquartered in Waltham, MA.

Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA.

Point Robotics Medtech, Inc. is a private company based in Taiwan that specializes in minimally invasive surgical technologies. In May 2020, the Taiwanese company completed its series-A fundraising from government funds, Taiwania Capital, and Translink Capital. Point Robotics Medtech will continue to focus on the development and regulatory approvals of next-generation products to maintain its leading position in the high-end surgical robotics market. Founded in 2016, the company has two major product lines\: the "Kinguide Robotic-Assisted Surgical System" and the "Kinguide Agile Hybrid Navigation System."

TWi Pharmaceuticals, Inc. operates as a technology-based special pharmaceutical company. The firm engages in the development and commercialization of high barrier generics drugs. Its products include donepezil hydrochloride tablets, megestrol acetate oral suspension, hydroquinone cream, guanfacine extended-release tablets and nifedipine extended-release tablets. The company was founded by Chih Ming Chen on December 1, 1997 and is headquartered in Taipei, Taiwan.